Collectively, these findings suggest that INO10 administration effectively mitigates Aβ accumulation, tau hyperphosphorylation, and neuroinflammation in 3xTg-AD mice, highlighting its potential as a promising therapeutic candidate for AD. Here, MAPT is linked to Alzheimer disease.